Physician

James Vh Uyeki, M.D.

According to 2025 Medicare claims, James Uyeki, M.D. (NPI: 1124187927) practices medical oncology in the Austin-Round Rock-San Marcos, TX market, with the plurality of this provider's patient population coming from Travis, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1972770303; TIN: 752131429) and primary practice location at 78745-1145. Uyeki is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483) and Honest MSSP of Michigan LLC (ACO ID: A5616), participating under the MSSP model.

Uyeki's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 934 traditional Medicare patients, billed 393,117 HCPCS/CPT codes, and received $7,171,448 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 2,318 prescription claims across 339 beneficiaries totaling $4,857,143 in drug costs, led by Brukinsa (Zanubrutinib). 2023 DME data shows 24 claims. Open Payments data shows 82 records totaling $684,622. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,753,489 to $7,171,448. Similarly, Part D prescription costs have moved sharply higher in recent years, from $740,202 to $4,857,143. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,271 to $4,588.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	442	132,146	$1,753,489
2016	647	146,453	$2,031,478
2017	744	155,448	$2,350,233
2018	904	303,271	$4,652,949
2019	992	464,842	$7,009,759
2020	936	429,401	$8,127,957
2021	955	439,179	$8,272,218
2022	1,043	523,253	$8,488,480
2023	988	565,878	$10,406,486
2024	934	393,117	$7,171,448

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	165	1,222	$740,202
2016	182	1,280	$889,951
2017	210	1,592	$1,541,982
2018	204	1,295	$1,339,612
2019	217	1,523	$1,631,164
2020	219	1,691	$2,367,868
2021	241	1,703	$3,115,473
2022	276	1,732	$3,326,356
2023	289	1,911	$3,650,767
2024	339	2,318	$4,857,143

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	153	$7,980
2016	N/R	141	$22,379
2017	13	116	$10,647
2018	N/R	129	$12,939
2019	N/R	11	$553
2020	N/R	31	$2,884
2021	N/R	11	$1,348
2022	N/R	N/R	N/R
2023	N/R	24	$1,845
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	428	1,949	$10
36415	Insertion of needle into vein for collection of blood sample	433	2,177	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	432	1,990	$8
83735	Magnesium level	325	1,438	$7
83615	Lactate dehydrogenase (enzyme) level	410	1,753	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	64	1,898	$910,681
Revlimid	Lenalidomide	55	1,449	$873,659
Pomalyst	Pomalidomide	23	623	$419,628
Tagrisso	Osimertinib Mesylate	21	630	$339,881
Inlyta	Axitinib	23	690	$298,095

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$49	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	79	$684,573	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Vh Uyeki, M.D.?

Tedicare shows public-source Medicare data for James Vh Uyeki, M.D. (NPI 1124187927), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Vh Uyeki, M.D. have ACO affiliation data?

James Vh Uyeki, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483) and Honest MSSP of Michigan LLC (MSSP, ACO ID A5616).

What billing organization is linked to James Vh Uyeki, M.D.?

James Vh Uyeki, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1972770303) in the available physician profile data.

Does James Vh Uyeki, M.D. have Open Payments data?

James Vh Uyeki, M.D. has 82 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.